Tadalafil
Product Images NDC 68071-2417

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-2417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2417 6)

Tadalafil 5mg tablet bottle label from NuCare Pharmaceuticals, Inc. The label indicates 60 tablets per bottle, each film-coated and oval-shaped light yellow to yellow with 'T5' debossed. It includes NDC code 68071-2417-6, storage instructions at controlled temperature 68-77°F, and prescription-only status.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The graph shows greater reduction in IPSS scores with Tadalafil 5 mg at each measured time point, with statistical significance indicated at 12 weeks (p < 0.01). The x-axis represents treatment duration in weeks; the y-axis represents change from baseline in IPSS Total Score.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A figure with four line graphs showing the effects of Tadalafil on blood pressure over time. The graphs display changes in standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure measured in mmHg, with time in hours on the x-axis and difference between Tadalafil and placebo on the y-axis.*

FDA Label Image

Figure2 (Tadalafil Figure2)

A dual line graph illustrating changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. The upper panel shows standing systolic BP; the lower panel shows supine systolic BP. Comparisons are made between Tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg, with time post-dose on the x-axis.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph showing the effect over time on systolic blood pressure (in mmHg) following administration of tadalafil or placebo combined with doxazosin, measured at two dosing times (08:00 and 20:00). The x-axis represents time after administration, and the y-axis displays changes in systolic blood pressure.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following five consecutive days of administration. The graph includes error bars and indicates concentration decreases over time for each dosing regimen.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration for Tadalafil 5 mg versus placebo, showing greater score reduction with Tadalafil. The graph indicates statistical significance with p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment period for Tadalafil 5 mg compared to placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS total score, with data points indicating statistical significance (*p<0.01) for Tadalafil at various time points.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph illustrating weeks of therapy (0, 4, 12, 26) on the x-axis and least squares mean change from baseline on the y-axis. It compares Tadalafil/Finasteride combination against Placebo/Finasteride, showing a decrease over time in mean change from baseline with statistical annotations for significance (p<0.001, p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil showing its molecular framework with distinctive fused ring systems and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.